徐州做四维的更佳时期(徐州有必要做4维彩超吗) (今日更新中)

WASHINGTON — The U.S. government on Tuesday will start distributing 30,000 doses of an experimental monoclonal antibody drug to fight COVID-19, the one President Donald Trump received last month.Over the weekend, the Food and Drug Administration agreed to allow emergency use of the therapeutic, casirivimab and imdevimab, made by Regeneron Pharmaceuticals Inc., for people with mild-to-moderate symptoms who are at high risk of developing serious illness because of their age or other medical conditions.The treatment was not authorized for use in sicker, hospitalized patients or those who need extra oxygen.President Donald Trump was given the therapeutic treatment when he contracted coronavirus in October. The Department of Health and Human Services said the federal government announced funding over the summer to support large-scale manufacturing of casirivimab and imdevimab.The agency will allocate “these government-owned doses to state and territorial health departments which, in turn, will determine which healthcare facilities receive the infusion drug,” reads a statement from HHS.“Beginning immediately, weekly allocations to state and territorial health departments will be proportionally based on confirmed COVID-19 cases in each state and territory over the previous seven days, based on data hospitals and state health departments enter into the HHS Protect data collection platform,” reads the HHS statement.Antibodies bind to the virus and help the immune system eliminate it. The Regeneron drug is a combo of two antibodies that seemed to do this well in lab tests.The emergency use authorization allows limited use of a drug while studies continue to test its safety and effectiveness. Early results suggest it may reduce COVID-19-related hospitalization or emergency room visits.The drugs are given as a one-time treatment through an IV and takes about an hour.Under federal contracts, the drugs for now will be supplied for free, although patients may have to pay part of the cost of the IV treatment. 2036

WASHINGTON (AP) — A new plan from Senate Republicans to award businesses, schools, and universities sweeping exemptions from lawsuits arising from inadequate coronavirus safeguards is putting Republicans and Democrats at loggerheads. The liability proposal promises to shield employers that negligently expose customers and workers to the coronavirus, limiting their legal exposure. That's according to a draft of the plan obtained by The Associated Press. Supporters say the proposal protects businesses and other employers who adhere to public-health guidelines in good faith. Opponents say it will permit wrongdoing to go unpunished. Lawmakers will consider the liability plan as they negotiate another coronavirus relief bill. 738

WASHINGTON — During his opening comments at a Congressional hearing on Tuesday, Dr. Anthony Fauci — the nation's top infectious disease expert — reiterated his confidence that a viable vaccine for COVID-19 would be developed by the end of the calendar year.Fauci says he believes that "it will be when, not if" that there will be millions of doses of a viable vaccine available by the end of 2020.Fauci made those comments Tuesday before the House Committee on Energy and Commerce. He is testifying along with Dr. Robert Redfield, the head of the Centers for Disease Control and Prevention, and Dr. Stephen Hahn, the head of the Food and Drug Administration.The hearing comes as coronavirus cases are rising in about half the states and political polarization is competing for attention with public health recommendations.The nation is emerging from weeks of stay-at-home orders and business shutdowns. But that's being done in an uneven way, with some states far less cautious than others.Fauci, formerly a fixture at daily coronavirus briefings held by the Trump administration at the White House, has continued to make regular media appearances. However, he has not appeared on camera at the White House in several weeks.The hearing takes place just days after President Donald Trump said at a rally on Saturday that he asked officials in his administration to "slow down" testing capacity in order to keep the number of confirmed cases steady. During a briefing on Monday press secretary, Kayleigh McEnany said that Trump's comments were made "in jest."However, in an interview with Scripps national politics editor Joe St. George, Trump did not specifically say if he asked officials to slow down testing, but added that "if it did slow down, frankly, I think we're way ahead of ourselves." 1803

WASHINGTON — The number of Americans seeking unemployment benefits fell last week to 787,000, a sign that job losses may have eased slightly but are still running at historically high levels. With confirmed infections having neared 60,000 in the past week, the highest level since July, many consumers have been unable or reluctant to shop, travel, dine out or congregate in crowds — a trend that has led some employers to keep cutting jobs. Several states, such as Ohio and Idaho, are reporting a record number of hospitalizations from the virus. 555

WASHINGTON — The Supreme Court has agreed to review a court decision that the NCAA has said blurred “the line between student-athletes and professionals.” A lower court ruling removed caps on education-related money that certain football and basketball players can receive. The case will be argued before the Supreme Court in 2021 with a decision expected before the end of June. The NCAA contends that antitrust law allows its member schools to impose certain restrictions, like on athlete compensation, in an effort to promote competitive equity and have a product for dans that is distinct from professional sports, according to USA Today. The NCAA claims a change to this arrangement would have larger implications on professional level sports leagues. An appeals court panel in May upheld a lower court ruling barring the NCAA from capping education-related compensation and benefits for student-athletes in Division I football and basketball programs. Such benefits could include cash payments for academic performance. The lower court's ruling said the NCAA could still set limits on compensation not connected to education. The association has revealed proposed rule changes that would allow athletes to make money from their names, images and likeness. Those proposed changes are set to be voted on in January. Division I conferences can still independently set their own rules. 1395

来源：资阳报